TY - JOUR T1 - Long-term treatment of generalised myasthenia gravis with FK506 (tacrolimus) JF - Journal of Neurology, Neurosurgery & Psychiatry JO - J Neurol Neurosurg Psychiatry SP - 448 LP - 450 DO - 10.1136/jnnp.2004.042176 VL - 76 IS - 3 AU - T Konishi AU - Y Yoshiyama AU - M Takamori AU - T Saida Y1 - 2005/03/01 UR - http://jnnp.bmj.com/content/76/3/448.abstract N2 - Efficacy and safety of long term use of FK506 (2–4.5 mg/day) for a maximum of two years were evaluated in 12 patients with generalised myasthenia gravis (MG). At the end of the study, eight patients (67%) showed improvement in either MG score or Activities in Daily Living score, and prednisolone dosage could be reduced in seven patients (58%), with a mean reduction ratio of 37%. Long term use of FK506 for MG can be more effective than short term administration, with no serious side effects. ER -